The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify eligible patients for the camizestrant regimen.
September 2026 Brief
The FDA granted accelerated approval to sevabertinib for HER2-mutant, nonsquamous NSCLC regardless of prior systemic therapy, based on SOHO-01 trial data.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer
2
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
3
FDA Expands Sevabertinib Approval to Treatment-Naive HER2-Mutant NSCLC
4
CAR T, Bispecifics, and Beyond: Dr Ku on the Evolving Paradigm in Gastric/GEJ Cancers
5